ZAFES Projects: Internal/External



Inflammatory gastro- intestinal diseases

An estimated 2.5 million Europeans and Americans suffer from chronic inflammatory diseases of the gastrointestinal (GI) tract. Unfortunately the root of the inflammation has not been definitively identified as yet, so there is currently no cure for these diseases. Even when inflamed segments of the gut are surgically removed, this does not always prevent further inflammation from erupting. For patients suffering from inflammatory bowel diseases, only palliative measures can be prescribed. The aim of these medications is to curtail the duration of acute inflammatory attacks and bring the patients into remission, as well as to sustain patients in the remission phase for as long as possible. To optimize this therapy, it would be highly desirable to formulate anti-inflammatory drugs in dosage forms with targeted delivery to the inflamed sites within the GI tract.

Within the ZAFES framework, Prof. Dr. Dressman of the Insitute of Pharmaceutical Technology and Prof. Dr. Jürgen Stein of the University clinic, together with an industrial partner, Röhm Deutschland GmbH, are seeking to produce formulations with release profiles within the GI tract optimized for the various inflammation patterns resulting from Crohn’s disease, ulcerative colitis etc. To date five patents have been filed and the first prototypes have already shown promise in preliminary clinical evaluations.

For more details see: News

< back